Search
diethylstilbestrol; DES (Stilphostol)
Tradename: Stilphostol (diethylstilbestrol diphosphate)
Indications:
1) palliative treatment of prostate cancer
a) 1-3 mg/day, increase in advanced cases
b) Stilphostol:
1] 50 mg TID
2] increase to > 200 mg TID
3] max dose is 1 gm
2) palliative treatment of breast cancer: 15 mg/day
3) Stilphostol is NOT indicated for treatment of any disorder in women
Adverse effects:
1) thrombophlebitis & venous thrombosis
2) breakthrough bleeding
3) nausea/vomiting
4) induction of estrogen-dependent tumors
5) women exposed in utero have increased risk of
a) infertility
b) preeclampsia
c) cervical intraepithelial neoplasia
d) breast cancer
e) clear-cell carcinoma [2]
Drug interactions:
1) antidepressants, beta blockers, corticosteroids, theophylline increase therapeutic effect & toxicity
2) antibiotics, barbiturates, phenytoin & rifampin decrease effectiveness of oral contraceptives
Interactions
drug adverse effects of estrogens
General
estrogen
Properties
MISC-INFO: elimination route LIVER
KIDNEY
Database Correlations
PUBCHEM cid=448537
References
- Drug Information & Medication Formulary, Veterans Affairs,
Central California Health Care System, 1st ed., Ravnan et al
eds, 1998 - not on National VA formulary
- Hoover RN et al
Adverse Health Outcomes in Women Exposed In Utero to
Diethylstilbestrol
N Engl J Med 2011; 365:1304-1314
PMID: 21991952
http://www.nejm.org/doi/full/10.1056/NEJMoa1013961